Bazedoxifene
Brand names: Duavee (combination)
Drug class:
Antineoplastic Agents
Usage of Bazedoxifene
Osteoporosis
Bazedoxifene/conjugated estrogens in fixed combination: Prevention of osteoporosis in postmenopausal women with an intact uterus.
Not FDA-labeled for treatment† [off-label] of osteoporosis in postmenopausal women in the US. Bazedoxifene commercially available in other countries for this use.
Not recommended for prevention of osteoporosis in premenopausal women† [off-label]; safety and efficacy not established.
Vasomotor Symptoms
Bazedoxifene/conjugated estrogens in fixed combination: Management of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus.
Relate drugs
- Abemaciclib (Systemic)
- Acyclovir (Systemic)
- Adenovirus Vaccine
- Aldomet
- Aluminum Acetate
- Aluminum Chloride (Topical)
- Ambien
- Ambien CR
- Aminosalicylic Acid
- Anacaulase
- Anacaulase
- Anifrolumab (Systemic)
- Antacids
- Anthrax Immune Globulin IV (Human)
- Antihemophilic Factor (Recombinant), Fc fusion protein (Systemic)
- Antihemophilic Factor (recombinant), Fc-VWF-XTEN Fusion Protein
- Antihemophilic Factor (recombinant), PEGylated
- Antithrombin alfa
- Antithrombin alfa
- Antithrombin III
- Antithrombin III
- Antithymocyte Globulin (Equine)
- Antivenin (Latrodectus mactans) (Equine)
- Apremilast (Systemic)
- Aprepitant/Fosaprepitant
- Articaine
- Asenapine
- Atracurium
- Atropine (EENT)
- Avacincaptad Pegol (EENT)
- Avacincaptad Pegol (EENT)
- Axicabtagene (Systemic)
- Clidinium
- Clindamycin (Systemic)
- Clonidine
- Clonidine (Epidural)
- Clonidine (Oral)
- Clonidine injection
- Clonidine transdermal
- Co-trimoxazole
- COVID-19 Vaccine (Janssen) (Systemic)
- COVID-19 Vaccine (Moderna)
- COVID-19 Vaccine (Pfizer-BioNTech)
- Crizanlizumab-tmca (Systemic)
- Cromolyn (EENT)
- Cromolyn (Systemic, Oral Inhalation)
- Crotalidae Polyvalent Immune Fab
- CycloSPORINE (EENT)
- CycloSPORINE (EENT)
- CycloSPORINE (Systemic)
- Cysteamine Bitartrate
- Cysteamine Hydrochloride
- Cysteamine Hydrochloride
- Cytomegalovirus Immune Globulin IV
- A1-Proteinase Inhibitor
- A1-Proteinase Inhibitor
- Bacitracin (EENT)
- Baloxavir
- Baloxavir
- Bazedoxifene
- Beclomethasone (EENT)
- Beclomethasone (Systemic, Oral Inhalation)
- Belladonna
- Belsomra
- Benralizumab (Systemic)
- Benzocaine (EENT)
- Bepotastine
- Betamethasone (Systemic)
- Betaxolol (EENT)
- Betaxolol (Systemic)
- Bexarotene (Systemic)
- Bismuth Salts
- Botulism Antitoxin (Equine)
- Brimonidine (EENT)
- Brivaracetam
- Brivaracetam
- Brolucizumab
- Brompheniramine
- Budesonide (EENT)
- Budesonide (Systemic, Oral Inhalation)
- Bulk-Forming Laxatives
- Bupivacaine (Local)
- BuPROPion (Systemic)
- Buspar
- Buspar Dividose
- Buspirone
- Butoconazole
- Cabotegravir (Systemic)
- Caffeine/Caffeine and Sodium Benzoate
- Calcitonin
- Calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate
- Calcium Salts
- Calcium, magnesium, potassium, and sodium oxybates
- Candida Albicans Skin Test Antigen
- Cantharidin (Topical)
- Capmatinib (Systemic)
- Carbachol
- Carbamide Peroxide
- Carbamide Peroxide
- Carmustine
- Castor Oil
- Catapres
- Catapres-TTS
- Catapres-TTS-1
- Catapres-TTS-2
- Catapres-TTS-3
- Ceftolozane/Tazobactam (Systemic)
- Cefuroxime
- Centruroides Immune F(ab′)2
- Cetirizine (EENT)
- Charcoal, Activated
- Chloramphenicol
- Chlorhexidine (EENT)
- Chlorhexidine (EENT)
- Cholera Vaccine Live Oral
- Choriogonadotropin Alfa
- Ciclesonide (EENT)
- Ciclesonide (Systemic, Oral Inhalation)
- Ciprofloxacin (EENT)
- Citrates
- Dacomitinib (Systemic)
- Dapsone (Systemic)
- Dapsone (Systemic)
- Daridorexant
- Darolutamide (Systemic)
- Dasatinib (Systemic)
- DAUNOrubicin and Cytarabine
- Dayvigo
- Dehydrated Alcohol
- Delafloxacin
- Delandistrogene Moxeparvovec (Systemic)
- Dengue Vaccine Live
- Dexamethasone (EENT)
- Dexamethasone (Systemic)
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine
- Dexmedetomidine (Intravenous)
- Dexmedetomidine (Oromucosal)
- Dexmedetomidine buccal/sublingual
- Dexmedetomidine injection
- Dextran 40
- Diclofenac (Systemic)
- Dihydroergotamine
- Dimethyl Fumarate (Systemic)
- Diphenoxylate
- Diphtheria and Tetanus Toxoids
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
- Diroximel Fumarate (Systemic)
- Docusate Salts
- Donislecel-jujn (Systemic)
- Doravirine, Lamivudine, and Tenofovir Disoproxil
- Doxepin (Systemic)
- Doxercalciferol
- Doxycycline (EENT)
- Doxycycline (Systemic)
- Doxycycline (Systemic)
- Doxylamine
- Duraclon
- Duraclon injection
- Dyclonine
- Edaravone
- Edluar
- Efgartigimod Alfa (Systemic)
- Eflornithine
- Eflornithine
- Elexacaftor, Tezacaftor, And Ivacaftor
- Elranatamab (Systemic)
- Elvitegravir, Cobicistat, Emtricitabine, and tenofovir Disoproxil Fumarate
- Emicizumab-kxwh (Systemic)
- Emtricitabine and Tenofovir Disoproxil Fumarate
- Entrectinib (Systemic)
- EPINEPHrine (EENT)
- EPINEPHrine (Systemic)
- Erythromycin (EENT)
- Erythromycin (Systemic)
- Estrogen-Progestin Combinations
- Estrogen-Progestin Combinations
- Estrogens, Conjugated
- Estropipate; Estrogens, Esterified
- Eszopiclone
- Ethchlorvynol
- Etranacogene Dezaparvovec
- Evinacumab (Systemic)
- Evinacumab (Systemic)
- Factor IX (Human), Factor IX Complex (Human)
- Factor IX (Recombinant)
- Factor IX (Recombinant), albumin fusion protein
- Factor IX (Recombinant), Fc fusion protein
- Factor VIIa (Recombinant)
- Factor Xa (recombinant), Inactivated-zhzo
- Factor Xa (recombinant), Inactivated-zhzo
- Factor XIII A-Subunit (Recombinant)
- Faricimab
- Fecal microbiota, live
- Fedratinib (Systemic)
- Fenofibric Acid/Fenofibrate
- Fibrinogen (Human)
- Flunisolide (EENT)
- Fluocinolone (EENT)
- Fluorides
- Fluorouracil (Systemic)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Flurbiprofen (EENT)
- Fluticasone (EENT)
- Fluticasone (Systemic, Oral Inhalation)
- Fluticasone and Vilanterol (Oral Inhalation)
- Ganciclovir Sodium
- Gatifloxacin (EENT)
- Gentamicin (EENT)
- Gentamicin (Systemic)
- Gilteritinib (Systemic)
- Glofitamab
- Glycopyrronium
- Glycopyrronium
- Gonadotropin, Chorionic
- Goserelin
- Guanabenz
- Guanadrel
- Guanethidine
- Guanfacine
- Haemophilus b Vaccine
- Hepatitis A Virus Vaccine Inactivated
- Hepatitis B Vaccine Recombinant
- Hetlioz
- Hetlioz LQ
- Homatropine
- Hydrocortisone (EENT)
- Hydrocortisone (Systemic)
- Hydroquinone
- Hylorel
- Hyperosmotic Laxatives
- Ibandronate
- Igalmi buccal/sublingual
- Imipenem, Cilastatin Sodium, and Relebactam
- Inclisiran (Systemic)
- Infliximab, Infliximab-dyyb
- Influenza Vaccine Live Intranasal
- Influenza Vaccine Recombinant
- Influenza Virus Vaccine Inactivated
- Inotuzumab
- Insulin Human
- Interferon Alfa
- Interferon Beta
- Interferon Gamma
- Intermezzo
- Intuniv
- Iodoquinol (Topical)
- Iodoquinol (Topical)
- Ipratropium (EENT)
- Ipratropium (EENT)
- Ipratropium (Systemic, Oral Inhalation)
- Ismelin
- Isoproterenol
- Ivermectin (Systemic)
- Ivermectin (Topical)
- Ixazomib Citrate (Systemic)
- Japanese Encephalitis Vaccine
- Kapvay
- Ketoconazole (Systemic)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (EENT)
- Ketorolac (Systemic)
- Ketotifen
- Lanthanum
- Lecanemab
- Lefamulin
- Lemborexant
- Lenacapavir (Systemic)
- Leniolisib
- Letermovir
- Letermovir
- Levodopa/Carbidopa
- LevoFLOXacin (EENT)
- LevoFLOXacin (Systemic)
- L-Glutamine
- Lidocaine (Local)
- Lidocaine (Systemic)
- Linezolid
- Lofexidine
- Loncastuximab
- Lotilaner (EENT)
- Lotilaner (EENT)
- Lucemyra
- Lumasiran Sodium
- Lumryz
- Lunesta
- Mannitol
- Mannitol
- Mb-Tab
- Measles, Mumps, and Rubella Vaccine
- Mecamylamine
- Mechlorethamine
- Mechlorethamine
- Melphalan (Systemic)
- Meningococcal Groups A, C, Y, and W-135 Vaccine
- Meprobamate
- Methoxy Polyethylene Glycol-epoetin Beta (Systemic)
- Methyldopa
- Methylergonovine, Ergonovine
- MetroNIDAZOLE (Systemic)
- MetroNIDAZOLE (Systemic)
- Miltown
- Minipress
- Minocycline (EENT)
- Minocycline (Systemic)
- Minoxidil (Systemic)
- Mometasone
- Mometasone (EENT)
- Moxifloxacin (EENT)
- Moxifloxacin (Systemic)
- Nalmefene
- Naloxone (Systemic)
- Natrol Melatonin + 5-HTP
- Nebivolol Hydrochloride
- Neomycin (EENT)
- Neomycin (Systemic)
- Netarsudil Mesylate
- Nexiclon XR
- Nicotine
- Nicotine
- Nicotine
- Nilotinib (Systemic)
- Nirmatrelvir
- Nirmatrelvir
- Nitroglycerin (Systemic)
- Ofloxacin (EENT)
- Ofloxacin (Systemic)
- Oliceridine Fumarate
- Olipudase Alfa-rpcp (Systemic)
- Olopatadine
- Omadacycline (Systemic)
- Osimertinib (Systemic)
- Oxacillin
- Oxymetazoline
- Pacritinib (Systemic)
- Palovarotene (Systemic)
- Paraldehyde
- Peginterferon Alfa
- Peginterferon Beta-1a (Systemic)
- Penicillin G
- Pentobarbital
- Pentosan
- Pilocarpine Hydrochloride
- Pilocarpine, Pilocarpine Hydrochloride, Pilocarpine Nitrate
- Placidyl
- Plasma Protein Fraction
- Plasminogen, Human-tmvh
- Pneumococcal Vaccine
- Polymyxin B (EENT)
- Polymyxin B (Systemic, Topical)
- PONATinib (Systemic)
- Poractant Alfa
- Posaconazole
- Potassium Supplements
- Pozelimab (Systemic)
- Pramoxine
- Prazosin
- Precedex
- Precedex injection
- PrednisoLONE (EENT)
- PrednisoLONE (Systemic)
- Progestins
- Propylhexedrine
- Protamine
- Protein C Concentrate
- Protein C Concentrate
- Prothrombin Complex Concentrate
- Pyrethrins with Piperonyl Butoxide
- Quviviq
- Ramelteon
- Relugolix, Estradiol, and Norethindrone Acetate
- Remdesivir (Systemic)
- Respiratory Syncytial Virus Vaccine, Adjuvanted (Systemic)
- RifAXIMin (Systemic)
- Roflumilast (Systemic)
- Roflumilast (Topical)
- Roflumilast (Topical)
- Rotavirus Vaccine Live Oral
- Rozanolixizumab (Systemic)
- Rozerem
- Ruxolitinib (Systemic)
- Saline Laxatives
- Selenious Acid
- Selexipag
- Selexipag
- Selpercatinib (Systemic)
- Sirolimus (Systemic)
- Sirolimus, albumin-bound
- Smallpox and Mpox Vaccine Live
- Smallpox Vaccine Live
- Sodium Chloride
- Sodium Ferric Gluconate
- Sodium Nitrite
- Sodium oxybate
- Sodium Phenylacetate and Sodium Benzoate
- Sodium Thiosulfate (Antidote) (Systemic)
- Sodium Thiosulfate (Protectant) (Systemic)
- Somatrogon (Systemic)
- Sonata
- Sotorasib (Systemic)
- Suvorexant
- Tacrolimus (Systemic)
- Tafenoquine (Arakoda)
- Tafenoquine (Krintafel)
- Talquetamab (Systemic)
- Tasimelteon
- Tedizolid
- Telotristat
- Tenex
- Terbinafine (Systemic)
- Tetrahydrozoline
- Tezacaftor and Ivacaftor
- Theophyllines
- Thrombin
- Thrombin Alfa (Recombinant) (Topical)
- Timolol (EENT)
- Timolol (Systemic)
- Tixagevimab and Cilgavimab
- Tobramycin (EENT)
- Tobramycin (Systemic)
- TraMADol (Systemic)
- Trametinib Dimethyl Sulfoxide
- Trancot
- Tremelimumab
- Tretinoin (Systemic)
- Triamcinolone (EENT)
- Triamcinolone (Systemic)
- Trimethobenzamide
- Tucatinib (Systemic)
- Unisom
- Vaccinia Immune Globulin IV
- Valoctocogene Roxaparvovec
- Valproate/Divalproex
- Valproate/Divalproex
- Vanspar
- Varenicline (Systemic)
- Varenicline (Systemic)
- Varenicline Tartrate (EENT)
- Vecamyl
- Vitamin B12
- Vonoprazan, Clarithromycin, and Amoxicillin
- Wytensin
- Xyrem
- Xywav
- Zaleplon
- Zirconium Cyclosilicate
- Zolpidem
- Zolpidem (Oral)
- Zolpidem (Oromucosal, Sublingual)
- ZolpiMist
- Zoster Vaccine Recombinant
- 5-hydroxytryptophan, melatonin, and pyridoxine
How to use Bazedoxifene
General
Administration
Oral Administration
Administer orally without regard to meals.
Swallow tablets whole.
Dosage
Available as bazedoxifene acetate; dosage expressed in terms of bazedoxifene.
Each tablet of bazedoxifene/conjugated estrogens in fixed combination contains bazedoxifene 20 mg and conjugated estrogens 0.45 mg.
Adults
Osteoporosis Prevention in Postmenopausal Women OralBazedoxifene 20 mg in fixed combination with conjugated estrogens 0.45 mg once daily.
Vasomotor Symptoms OralBazedoxifene 20 mg in fixed combination with conjugated estrogens 0.45 mg once daily.
Special Populations
When bazedoxifene is used in fixed combination with conjugated estrogens, dosage requirements for conjugated estrogens should be considered.
Hepatic Impairment
Bazedoxifene/conjugated estrogens in fixed combination: Contraindicated. (See Contraindications and Hepatic Effects under Cautions.)
Renal Impairment
Bazedoxifene/conjugated estrogens in fixed combination: Not recommended.
Warnings
Contraindications
Warnings/Precautions
Warnings
Use of Fixed CombinationsWhen used in fixed combination with conjugated estrogens, consider the cautions, precautions, contraindications, and interactions associated with conjugated estrogens.
Cardiovascular EffectsManage risk factors for cardiovascular disorders, arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, obesity), and/or venous thromboembolism (VTE) (e.g., personal or family history of VTE, obesity, systemic lupus erythematosus). Do not use estrogens for prevention of cardiovascular disease.
Increased risk of stroke and VTE observed in postmenopausal women receiving daily dosages of oral conjugated estrogens alone; increased risk of VTE observed with individual use of estrogen agonists-antagonists (e.g., bazedoxifene). Not known if risk of VTE with bazedoxifene/conjugated estrogens in fixed combination is different from other estrogen preparations.
Discontinue therapy immediately if VTE or stroke occurs or is suspected.
Discontinue therapy at least 4–6 weeks prior to surgery associated with increased risk of thromboembolism or during periods of prolonged immobilization, if possible. Do not resume therapy until patient is fully ambulatory. Advise women receiving the drug to ambulate periodically during travel involving prolonged immobilization.
Increased BP reported in women receiving estrogens; attributed to idiosyncratic reactions associated with estrogens. Generalized effect of estrogens on BP not observed in large, randomized, placebo-controlled study.
May increase plasma HDL-cholesterol and HDL2-cholesterol subfraction concentrations, decrease LDL-cholesterol concentrations, and increase triglyceride concentrations.
Estrogens may cause some degree of fluid retention. Carefully observe women with conditions that might be aggravated by fluid retention (e.g., cardiac dysfunction, renal impairment) when receiving estrogens.
DementiaIncreased risk of probable dementia in women 65–79 years of age receiving daily dosages of conjugated estrogens alone in WHI Memory Study. Not known whether this finding applies to younger postmenopausal women.
Do notuse estrogen therapy for prevention of dementia.
GU EffectsIncreased risk of endometrial cancer reported in postmenopausal women with an intact uterus who use estrogen alone. Use of bazedoxifene/conjugated estrogens in fixed combination reduces risk of endometrial hyperplasia (possible precUrsor to endometrial cancer).
Clinical surveillance important for all women receiving bazedoxifene/conjugated estrogens in fixed combination. Rule out malignancy in postmenopausal women with undiagnosed persistent or recurrent abnormal genital bleeding. Do not use additional estrogens concurrently with such therapy as this may increase risk of endometrial hyperplasia.
Other Warnings/Precautions
Fetal/Neonatal Morbidity and MortalityMay cause fetal harm. If used during pregnancy or if woman becomes pregnant, apprise of potential fetal hazard.
Body Mass IndexSystemic exposure of bazedoxifene predicted to be reduced by 17% in women with body mass index (BMI) >27 kg/m2. Reduced bazedoxifene exposure may be associated with increased risk of endometrial hyperplasia.
Regardless of BMI, clinical surveillance important for all women receiving bazedoxifene/conjugated estrogens in fixed combination. Rule out malignancy in postmenopausal women with undiagnosed persistent or recurrent abnormal genital bleeding.
CarcinogenicityNo increased risk of invasive breast cancer observed in postmenopausal women receiving daily dosages of conjugated estrogens alone. Increased incidence of abnormal mammograms requiring further evaluation reported with estrogen alone.
Effect of bazedoxifene/conjugated estrogens in fixed combination on breast cancer risk unknown. Annual breast examinations by clinician and monthly breast self-examinations recommended in all women receiving such therapy. Schedule mammography based on patient age, risk factors, and prior mammogram results.
Epidemiologic studies suggest use of estrogen-only products for ≥5 years associated with increased risk of ovarian cancer. Data inconsistent regarding duration of exposure associated with this risk. Effect of bazedoxifene/conjugated estrogens in fixed combination on ovarian cancer risk unknown.
Endocrine and Metabolic EffectsEstrogen therapy increases thyroxine-binding globulin (TBG) concentrations. Bazedoxifene/conjugated estrogens in fixed combination also may increase TBG concentrations leading to increased circulating total thyroid hormone. Increased thyroid hormone dosage may be required in women receiving thyroid hormone therapy. Monitor thyroid function in such patients to maintain free thyroid hormone concentrations in acceptable range.
Use of estrogens may be associated with increased plasma triglyceride concentrations leading to pancreatitis in women with preexisting hypertriglyceridemia. Consider discontinuance of therapy if pancreatitis occurs.
Bazedoxifene/conjugated estrogens in fixed combination may cause impaired Glucose tolerance.
May decrease free hormone concentrations (e.g., Testosterone, estradiol). Concentrations of certain binding proteins may be elevated (e.g., corticosteroid-binding globulin [CBG], sex hormone binding globulin [SHBG]) leading to increased total circulating corticosteroids and sex steroids.
May increase concentrations of certain plasma proteins (e.g., angiotensinogen/renin substrate, α1-antitrypsin, ceruloplasmin).
Exacerbation of Other ConditionsEstrogen therapy may exacerbate asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas; use with caution in women with these conditions.
GI EffectsTwofold or fourfold increased risk of gallbladder disease requiring surgery reported in postmenopausal women receiving estrogens.
Hematologic EffectsBazedoxifene/conjugated estrogens in fixed combination may cause accelerated PT, PTT, or platelet aggregation time. Also may increase platelet count and increase factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and β-thromboglobulin.
Hepatic EffectsBazedoxifene/conjugated estrogens in fixed combination not studied in women with hepatic impairment or history of cholestatic jaundice.
Contraindicated in patients with hepatic impairment. (See Contraindications under Cautions.) Use with caution in women with history of cholestatic jaundice associated with previous estrogen use or pregnancy. If such conditions recur, discontinue therapy.
Hereditary AngioedemaEstrogens may exacerbate symptoms of angioedema in women with hereditary angioedema.
HypocalcemiaUse estrogens with caution in women with hypoparathyroidism; may induce hypocalcemia in such patients.
Laboratory MonitoringMonitoring serum follicle-stimulating hormone (FSH) and estradiol concentrations not shown to be useful in management of moderate to severe vasomotor symptoms.
Ocular EffectsRetinal vascular thrombosis reported in patients receiving estrogens. Discontinue bazedoxifene/conjugated estrogens in fixed combination pending diagnostic evaluation for sudden partial or complete loss of vision or sudden onset of proptosis, diplopia, or migraine. Permanently discontinue therapy if ophthalmologic examination reveals papilledema or retinal vascular lesions.
Use in Premenopausal WomenNot recommended. Efficacy and safety not established.
Use with Progestins, Estrogens, or Estrogen Agonists-AntagonistsDo not use progestins, additional estrogens, or additional estrogen agonists-antagonists concomitantly with bazedoxifene/conjugated estrogens in fixed combination.
Specific Populations
PregnancyCategory X. (See Fetal/Neonatal Morbidity and Mortality under Cautions.)
LactationNot known whether distributed into milk. Estrogen use in nursing women shown to decrease quantity and quality of milk. Do not use in nursing women.
Pediatric UseNot indicated for use in pediatric patients.
Geriatric UseBazedoxifene/conjugated estrogens in fixed combination not recommended in women >75 years of age.
No overall differences in safety or efficacy observed in women 65–74 years of age compared with younger women. Greater sensitivity in some older women cannot be ruled out.
Hepatic ImpairmentBazedoxifene/conjugated estrogens in fixed combination contraindicated in patients with hepatic impairment. (See Contraindications under Cautions.)
Renal ImpairmentBazedoxifene/conjugated estrogens in fixed combination not recommended in women with renal impairment. Pharmacokinetics, safety, and efficacy of the drug not studied in such patients.
Study results with bazedoxifene 20 mg once daily alone in postmenopausal women with mild, moderate, or severe renal impairment showed no increase in incidence or severity of adverse effects compared with placebo.
Common Adverse Effects
Nausea, diarrhea, dyspepsia, upper abdominal pain, muscle spasms, neck pain, dizziness, nasopharyngitis, oropharyngeal pain.
What other drugs will affect Bazedoxifene
Formal drug interaction studies not performed to date with bazedoxifene/conjugated estrogens in fixed combination.
Bazedoxifene metabolized by UGT enzymes in the intestinal tract and liver.
Bazedoxifene undergoes little or no metabolism by CYP isoenzymes. Does not induce or inhibit the activity of CYP isoenzymes.
Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes
Drugs metabolized by CYP isoenzymes: Clinically important interactions with bazedoxifene unlikely.
Inducers of CYP3A4: May decrease estrogen plasma concentrations and result in decreased therapeutic effect and/or changes in uterine bleeding.
Inhibitors of CYP3A4: May increase conjugated estrogen exposures resulting in increased risk of endometrial hyperplasia. If a CYP3A4 inhibitor is used concomitantly with bazedoxifene/conjugated estrogens in fixed combination for >30 days, rule out malignancy in postmenopausal women with undiagnosed persistent or recurrent abnormal genital bleeding.
Drugs Affecting or Metabolized by UGT
Inducers of UGT: Metabolism of bazedoxifene may be increased; decreased bazedoxifene exposures may be associated with increased risk of endometrial hyperplasia. Rule out malignancy in postmenopausal women with undiagnosed persistent or recurrent abnormal genital bleeding.
Specific Drugs
Drug
Interaction
Comments
Antacids (aluminum hydroxide and magnesium hydroxide)
Increased bazedoxifene AUC and decreased peak concentrations
Antifungals, azoles (itraconazole, ketoconazole)
Possible increased conjugated estrogen exposure leading to increased risk of endometrial hyperplasia
If used concomitantly for >30 days, rule out malignancy in postmenopausal women with undiagnosed persistent or recurrent abnormal genital bleeding
Possible decreased bazedoxifene exposure resulting in possible increased risk of endometrial hyperplasia
Possible decreased estrogen concentrations resulting in decreased therapeutic effect and/or changes in uterine bleeding
Rule out malignancy in postmenopausal women with undiagnosed persistent or recurrent abnormal genital bleeding
Grapefruit juice
Possible increased conjugated estrogen exposure leading to increased risk of endometrial hyperplasia
If used concomitantly for >30 days, rule out malignancy in postmenopausal women with undiagnosed persistent or recurrent abnormal genital bleeding
Estrogens and estrogen agonists-antagonists
No clinically important pharmacokinetic interactions between conjugated estrogens and bazedoxifene
Avoid concomitant use of additional estrogens or estrogen agonists-antagonists
HMG-CoA reductase inhibitors (atorvastatin)
No substantial effect on atorvastatin or bazedoxifene pharmacokinetics
Macrolide antibiotics (azithromycin, clarithromycin, erythromycin)
Azithromycin: No substantial effect on bazedoxifene pharmacokinetics
Clarithromycin, erythromycin: Possible increased conjugated estrogen exposure leading to increased risk of endometrial hyperplasia
Clarithromycin, erythromycin: If used concomitantly for >30 days, rule out malignancy in postmenopausal women with undiagnosed persistent or recurrent abnormal genital bleeding
NSAIAs (ibuprofen)
No substantial effect on ibuprofen or bazedoxifene pharmacokinetics
Phenobarbital
Possible decreased bazedoxifene exposure resulting in possible increased risk of endometrial hyperplasia
Possible decreased estrogen concentrations resulting in decreased therapeutic effect and/or changes in uterine bleeding
Rule out malignancy in postmenopausal women with undiagnosed persistent or recurrent abnormal genital bleeding
Phenytoin
Possible decreased bazedoxifene exposure resulting in possible increased risk of endometrial hyperplasia
Rule out malignancy in postmenopausal women with undiagnosed persistent or recurrent abnormal genital bleeding
Progestins
Avoid concomitant use
Rifampin
Possible decreased bazedoxifene exposure resulting in possible increased risk of endometrial hyperplasia
Possible decreased estrogen concentrations resulting in decreased therapeutic effect and/or changes in uterine bleeding
Rule out malignancy in postmenopausal women with undiagnosed persistent or recurrent abnormal genital bleeding
Ritonavir
Possible increased conjugated estrogen exposure leading to increased risk of endometrial hyperplasia
If used concomitantly for >30 days, rule out malignancy in postmenopausal women with undiagnosed persistent or recurrent abnormal genital bleeding
St. John's wort (Hypericum perforatum)
Possible decreased estrogen concentrations resulting in decreased therapeutic effect and/or changes in uterine bleeding
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions